What You Should Know:
- A nationwide U.S. study of more than 893,000 adults provides solid evidence confirming that mRNA booster immunizations extend protection against moderate and severe COVID for four to five months.
- These findings, published in The BMJ, provide a more complete understanding of the effectiveness and durability of third and fourth doses of the mRNA vaccines, informing policymakers and providing individuals with confirmation of the importance and value of
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
Sanofi Cuts Price of Lantus Insulin by 78% & Caps Out of Pocket Costs at $35 for All Patients
What You Should Know:
- Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insurance. The price cut goes into effect January 1, 2024.
- The price cut milestone comes in addition to decisions taken in June 2022 to lower diabetes medicines costs: the launch of an unbranded Lantus biologic at -60% versus Lantus list price, and a cap on out-of-pocket costs on insulin to $35 for all people
Read More
Protai Raises $20M to Build an Oncology Drug Discovery Pipeline
What You Should Know:
- Protai, a proteomics and AI-powered drug discovery startup revolutionizing the way new drugs are discovered, today announced a $12 million extension of its seed round, bringing the total amount to $20M.
- The round includes existing investors Grove Ventures and Pitango Healthcare and was joined by Copenhagen-based Maj Invest Equity Fund. The additional funding will be used to build Protai’s oncology drug discovery pipeline, expand data
Read More
Pfizer Acquires Seagen for $43B to Tackle Cancer
What You Should Know:
- Pfizer announced it will acquire biotechnology company Seagen for $229 per Seagen share in cash, for a total enterprise value of approximately $43 billion. The proposed combination enhances Pfizer’s position as a leading company in Oncology.
Seagen’s medicines, late-stage development programs and pioneering expertise in Antibody-Drug Conjugates (ADCs) strongly complement Pfizer’s Oncology portfolio.
Seagen Background
Seagen is a pioneer in ADC technology, with
Read More
H1 Launches Advanced Diversity and Clinical Trial Performance Insights
What You Should Know:
- H1, the connecting force for global healthcare provider, clinical, science, and research information, today announced the availability of indication-level diversity insights in addition to institution, provider, and patient diversity data within its Trial Landscape solution.
- Additionally, H1 has successfully onboarded its first customer – a top 20 pharmaceutical company – onto the H1 Data Network, a new solution that aggregates sponsor-contributed site and
Read More
Drug Development: Allucent Expands Use of Medidata Clinical Cloud
What You Should Know:
- Medidata announced that Allucent, a contract research organization (CRO) bringing innovation to biopharma companies, is expanding the global use of Medidata’s Clinical Cloud to advance its end-to-end clinical trial operations offering.
- The agreement expands Allucent’s existing utilization of Medidata technologies. These include Rave EDC, eCOA, RTSM,
Read More
Clarapath Acquires AI-Powered Digital Pathology Platform Crosscope
What You Should Know:
- Clarapath, a robotics company aimed at catalyzing change in the way pathology laboratories process human and animal tissue acquires Mountain View, CA-based Crosscope. Financial details of the acquisition were not disclosed.
- Crosscope is a digital pathology company with a turnkey imaging solution providing best-in-class workflow tools and slide management along with artificial intelligence (AI) and machine learning (ML) technology to assist pathologists with better
Read More
C2i Genomics, Riken Genesis Expands AI-Powered Whole-Genome MRD Cancer Detection Across Japan
What You Should Know:
- C2i Genomics, a cancer intelligence company, today announced a collaboration with Riken Genesis Co., Ltd. (RG), a company specializing in providing the service of personalized medicine based on contract analysis of next-generation sequencing and exomes. The two companies have entered a collaboration agreement to bring MRD cancer monitoring to Japan for pharmaceutical and clinical research.
- Under this agreement, RG will work with C2i Genomics to commercialize
Read More
Eli Lilly Cuts Insulin Prices by 70%, Caps Patient Costs at $35 Per Month
What You Should Know:
- Eli Lilly and Company today announced price reductions of 70% for its most commonly prescribed insulins and an expansion of its Insulin Value Program that caps patient out-of-pocket costs at $35 or less per month at participating retail pharmacies.
- The historic price cut makes it easier to access Lily insulin for Americans who may have difficulty navigating a complex healthcare system that may keep them from getting affordable
Read More
M&A: ArisGlobal to Acquire Amplexor Life Sciences
What You Should Know:
- ArisGlobal, the leading provider of life sciences software designed to automate core drug development functions, acquired Amplexor Life Sciences, a global provider of regulatory, quality, and safety software solutions. Financial details of the acquisition were not disclosed.
- This combined product ecosystem provides a new opportunity for life sciences companies, bringing together best-in-breed solutions to form a cohesive solution serving customers’
Read More
